Fintan is the CEO and Founder of PharmaVentures, a premier transaction advisory firm and a leading international management company in partnering, MA deals and alliances. In 1992, Fintan co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in partnering, the licensing of intellectual property, and M&A. In 1997 this company became PharmaVentures. Over nearly three decades, Fintan built PharmaVentures into a global player in supporting transactions for blue-chip corporations and emerging innovator corporations. In that time the firm has delivered more than 1,000 transaction-related assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic, and OTC companies. Its clients have also included major banks, investment/merchant banks, as well as private equity and venture capital groups. In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking data and analytics. Thousands of customers from around the world either bought or subscribed to these PharmaDeals publications. The PharmaDeals business was sold to IMS Health (now IQVIA) in Aug 2012. Dr. Walton majored in Genetics at Trinity College Dublin, Ireland where he also gained a Ph.D. researching cell proliferation in yeast. Before his entrepreneurial activities at PharmaVentures, Fintan had built his R&D and commercial experience in biotechnology within management positions at Bass and Celltech plc (1982-1992).